HK1086573A1 - Quinazoline derivatives for treatment of cancer - Google Patents

Quinazoline derivatives for treatment of cancer

Info

Publication number
HK1086573A1
HK1086573A1 HK06106582A HK06106582A HK1086573A1 HK 1086573 A1 HK1086573 A1 HK 1086573A1 HK 06106582 A HK06106582 A HK 06106582A HK 06106582 A HK06106582 A HK 06106582A HK 1086573 A1 HK1086573 A1 HK 1086573A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
HK06106582A
Other languages
English (en)
Inventor
Heron Nicola Murdoch
Pasquet Georges Rene
Mortlock Andrew Austen
Jung Frederic Henri
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1086573A1 publication Critical patent/HK1086573A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK06106582A 2003-04-16 2006-06-08 Quinazoline derivatives for treatment of cancer HK1086573A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290951 2003-04-16
PCT/GB2004/001614 WO2004094410A1 (en) 2003-04-16 2004-04-14 Chemical compounds

Publications (1)

Publication Number Publication Date
HK1086573A1 true HK1086573A1 (en) 2006-09-22

Family

ID=33305809

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06106582A HK1086573A1 (en) 2003-04-16 2006-06-08 Quinazoline derivatives for treatment of cancer

Country Status (23)

Country Link
US (1) US7691867B2 (xx)
EP (1) EP1613619B1 (xx)
JP (1) JP4709139B2 (xx)
KR (1) KR20060003351A (xx)
CN (1) CN1809557B (xx)
AR (1) AR043875A1 (xx)
AT (1) ATE390422T1 (xx)
AU (1) AU2004232527A1 (xx)
BR (1) BRPI0409427A (xx)
CA (1) CA2522079A1 (xx)
CL (1) CL2004000797A1 (xx)
CO (1) CO5640037A2 (xx)
DE (1) DE602004012725T2 (xx)
ES (1) ES2301981T3 (xx)
HK (1) HK1086573A1 (xx)
IS (1) IS8125A (xx)
MX (1) MXPA05011076A (xx)
NO (1) NO20054842L (xx)
RU (1) RU2005135337A (xx)
TW (1) TW200510392A (xx)
UY (1) UY28271A1 (xx)
WO (1) WO2004094410A1 (xx)
ZA (1) ZA200508372B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2323215C2 (ru) * 2001-12-24 2008-04-27 Астразенека Аб Замещенные производные хиназолина как ингибиторы ауроракиназы
DK1847539T3 (da) * 2002-12-24 2009-11-09 Astrazeneca Ab Quinazolin-derivater
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
UA85706C2 (xx) 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-феніламінохіназолін-6-іламіди$4-фениламинохиназолин-6-иламиды
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
WO2006040522A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinoline derivatives
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
PL1819698T3 (pl) 2004-11-17 2011-08-31 Rexahn Pharmaceuticals Inc Pochodne 1-[(6-podstawione alkoksychinoksalinylo)aminokarbonylo]-4-(hetero)arylopiperazyny
WO2006129064A1 (en) * 2005-05-28 2006-12-07 Astrazeneca Ab Quinazolines and their use as aurora kinase inhibitors
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
JP2009508922A (ja) * 2005-09-22 2009-03-05 アストラゼネカ アクチボラグ ４−アミノピラゾール誘導体の製造方法
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
WO2007099317A1 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinazoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN103382158B (zh) * 2013-07-29 2015-11-18 张家港市大伟助剂有限公司 一种2-环戊基氨基乙醇的制备方法
BR112016005317A2 (pt) * 2013-09-19 2017-09-12 Centre Nat Rech Scient derivados de quinazolina e seu uso como inibidores de dna metiltransferase

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
TW321649B (xx) * 1994-11-12 1997-12-01 Zeneca Ltd
DE69622183D1 (de) * 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
US6919338B2 (en) * 2000-06-28 2005-07-19 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
RU2323215C2 (ru) * 2001-12-24 2008-04-27 Астразенека Аб Замещенные производные хиназолина как ингибиторы ауроракиназы
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION
ATE412657T1 (de) 2002-12-24 2008-11-15 Astrazeneca Ab Therapeutische quinazolin-derivate
MXPA05006920A (es) * 2002-12-24 2006-02-10 Astrazeneca Ab Compuestos de quinazolina.
DK1847539T3 (da) * 2002-12-24 2009-11-09 Astrazeneca Ab Quinazolin-derivater
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
TW200510392A (en) 2005-03-16
CN1809557A (zh) 2006-07-26
EP1613619B1 (en) 2008-03-26
DE602004012725T2 (de) 2009-04-16
WO2004094410A1 (en) 2004-11-04
IS8125A (is) 2005-11-11
JP2006523660A (ja) 2006-10-19
CL2004000797A1 (es) 2005-05-27
CO5640037A2 (es) 2006-05-31
CN1809557B (zh) 2012-07-04
ZA200508372B (en) 2007-04-25
UY28271A1 (es) 2004-11-30
JP4709139B2 (ja) 2011-06-22
BRPI0409427A (pt) 2006-04-18
CA2522079A1 (en) 2004-11-04
ATE390422T1 (de) 2008-04-15
DE602004012725D1 (de) 2008-05-08
US20060270692A1 (en) 2006-11-30
NO20054842L (no) 2005-11-08
US7691867B2 (en) 2010-04-06
AU2004232527A1 (en) 2004-11-04
KR20060003351A (ko) 2006-01-10
ES2301981T3 (es) 2008-07-01
AR043875A1 (es) 2005-08-17
RU2005135337A (ru) 2006-06-10
EP1613619A1 (en) 2006-01-11
MXPA05011076A (es) 2006-01-24

Similar Documents

Publication Publication Date Title
HK1086573A1 (en) Quinazoline derivatives for treatment of cancer
HK1204476A1 (en) Compounds and methods for treatment of cancer
EP1667680A4 (en) COMBINED METHODS OF TREATING CANCER
EP1613308A4 (en) CANCER TREATMENT METHODS
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
EP1663259A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
SI1948180T1 (sl) Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
IL164599A0 (en) Combination therapy for the treatment of cancer
HK1117780A1 (en) Compounds and methods for the treatment of cancer
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
IL175689A0 (en) Enoxaparin for the treatment of cancer
EP1677805A4 (en) TREATMENT OF PANCREATIC CANCER
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0329416D0 (en) Treatment of cancer
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung
PL1680405T3 (pl) Pochodne bengamidu i ich zastosowanie do leczenia chorób nowotworowych
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
GB0410379D0 (en) Treatment of cancer
GB0423273D0 (en) Treatment of cancer
EP1616190A4 (en) DIAGNOSIS OF CANCER AT AN ADVANCED STAGE
GB0327667D0 (en) Treatment of cancer
AU2003217925A1 (en) Treatment of metastatic institute for cancer
GB0324482D0 (en) Methods for the treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130414